114 related articles for article (PubMed ID: 2503975)
1. Immunotherapy of treated BL/LL cases with BCG: histopathological, immunohistological and bacteriological assessments.
Katoch K; Natrajan M; Narayanan RB; Katoch VM
Acta Leprol; 1989; 7 Suppl 1():153-5. PubMed ID: 2503975
[TBL] [Abstract][Full Text] [Related]
2. Treatment of bacilliferous BL/LL cases with combined chemotherapy and immunotherapy.
Katoch K; Katoch VM; Natrajan M; Bhatia AS; Sreevatsa ; Gupta UD; Sharma VD; Shivannavar CT; Patil MA; Bharadwaj VP
Int J Lepr Other Mycobact Dis; 1995 Jun; 63(2):202-12. PubMed ID: 7602215
[TBL] [Abstract][Full Text] [Related]
3. 10-12 years follow-up of highly bacillated BL/LL leprosy patients on combined chemotherapy and immunotherapy.
Katoch K; Katoch VM; Natrajan M; Sreevatsa ; Gupta UD; Sharma VD; Shivanavar CT
Vaccine; 2004 Sep; 22(27-28):3649-57. PubMed ID: 15315844
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of immunotherapeutic efficacy of BCG and mw vaccines in patients of borderline lepromatous and lepromatous leprosy.
Narang T; Kaur I; Kumar B; Radotra BD; Dogra S
Int J Lepr Other Mycobact Dis; 2005 Jun; 73(2):105-14. PubMed ID: 16830653
[TBL] [Abstract][Full Text] [Related]
5. Histological changes with combined chemotherapy and immunotherapy in highly bacillated lepromatous leprosy.
Natarajan M; Katoch K; Bagga AK; Katoch VM
Acta Leprol; 1992; 8(2):79-86. PubMed ID: 1293915
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of far-advanced lepromatous leprosy patients with low-dose convit vaccine along with multidrug therapy (Calcutta trial).
Majumder V; Mukerjee A; Hajra SK; Saha B; Saha K
Int J Lepr Other Mycobact Dis; 1996 Mar; 64(1):26-36. PubMed ID: 8627110
[TBL] [Abstract][Full Text] [Related]
7. Clinical and bacteriological progress of highly bacillated BL-LL patients discontinuing treatment after different periods of MDT.
Katoch K; Natarajan M; Bagga A; Katoch VM
Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):248-54. PubMed ID: 2071982
[TBL] [Abstract][Full Text] [Related]
8. Combined 12-month WHO/MDT MB regimen and Mycobacterium w. vaccine in multibacillary leprosy: a follow-up of 136 patients.
Kaur I; Dogra S; Kumar B; Radotra BD
Int J Lepr Other Mycobact Dis; 2002 Sep; 70(3):174-81. PubMed ID: 12483965
[TBL] [Abstract][Full Text] [Related]
9. Detection of viable organisms in leprosy patients treated with multidrug therapy.
Gupta UD; Katoch K; Singh HB; Natrajan M; Sharma VD; Katoch VM
Acta Leprol; 1999; 11(3):89-92. PubMed ID: 10544720
[TBL] [Abstract][Full Text] [Related]
10. Histologic responses in sixty multibacillary leprosy patients inoculated with autoclaved Mycobacterium leprae and live BCG.
Meyers WM; McDougall AC; Fleury RN; Neves R; Reyes O; Binford CH
Int J Lepr Other Mycobact Dis; 1988 Jun; 56(2):302-9. PubMed ID: 3045226
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy with a mixture of Mycobacterium leprae and BCG in different forms of leprosy and in Mitsuda-negative contacts.
Convit J; Aranzazu N; Ulrich M; Pinardi ME; Reyes O; Alvarado J
Int J Lepr Other Mycobact Dis; 1982 Dec; 50(4):415-24. PubMed ID: 6763002
[TBL] [Abstract][Full Text] [Related]
12. New lesions after MDT in PB and MB leprosy: a report of 28 cases.
Kar HK; Sharma P
Indian J Lepr; 2008; 80(3):247-55. PubMed ID: 19432355
[TBL] [Abstract][Full Text] [Related]
13. A longitudinal study of immunologic reactivity in leprosy patients treated with immunotherapy.
Rada E; Ulrich M; Aranzazu N; Santaella C; Gallinoto M; Centeno M; Rodriguez V; Convit J
Int J Lepr Other Mycobact Dis; 1994 Dec; 62(4):552-8. PubMed ID: 7868953
[TBL] [Abstract][Full Text] [Related]
14. Are viable Mycobacterium leprae present in lepromatous patients after completion of 12 months' and 24 months' multi-drug therapy?
Ebenezer GJ; Daniel S; Norman G; Daniel E; Job CK
Indian J Lepr; 2004; 76(3):199-206. PubMed ID: 15835604
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of lepromin-negative borderline leprosy patients with low-dose Convit vaccine as an adjunct to multidrug therapy; a six-year follow-up study in Calcutta.
Chaudhury S; Hajra SK; Mukerjee A; Saha B; Majumdar V; Chattapadhya D; Saha K
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):56-62. PubMed ID: 9207754
[TBL] [Abstract][Full Text] [Related]
16. Histopathological monitoring of an immunotherapeutic trial with Mycobacterium w.
Mukherjee A; Zaheer SA; Sharma AK; Misra RS; Kar HK; Mukherjee R; Talwar GP
Int J Lepr Other Mycobact Dis; 1992 Mar; 60(1):28-35. PubMed ID: 1602191
[TBL] [Abstract][Full Text] [Related]
17. BCG immunotherapy as an adjunct to chemotherapy in BL-lL patients--its effect on clinical regression, reaction severity, nerve function, lepromin conversion, bacterial/antigen clearance and 'persister' M. leprae.
Shetty VP; Mistry NF; Wakade AV; Ghate SD; Capadia GD; Pai VV
Lepr Rev; 2013 Mar; 84(1):23-40. PubMed ID: 23741880
[TBL] [Abstract][Full Text] [Related]
18. Analysis of quantitative relationship between viability determination in leprosy by MFP, ATP bioluminescence and gene amplification assay.
Gupta UD; Katoch K; Sharma RK; Singh HB; Natragan M; Singh D; Sharma VD; Chauhan DS; Das R; Srivastava K; Katoch VM
Int J Lepr Other Mycobact Dis; 2001 Dec; 69(4):328-34. PubMed ID: 12035294
[TBL] [Abstract][Full Text] [Related]
19. Results of a modified WHO regimen in highly bacilliferous BL/LL patients.
Katoch K; Ramu G; Ramanathan U; Sengupta U; Sreevatsa ; Sharma VD; Shivannavar CT; Katoch VM
Int J Lepr Other Mycobact Dis; 1989 Jun; 57(2):451-7. PubMed ID: 2664042
[TBL] [Abstract][Full Text] [Related]
20. Effect of chemotherapy on viability of Mycobacterium leprae as determined by ATP content, morphological index and FDA-EB fluorescent staining.
Katoch VM; Katoch K; Ramanathan U; Sharma VD; Shivannavar CT; Datta AK; Bharadwaj VP
Int J Lepr Other Mycobact Dis; 1989 Sep; 57(3):615-21. PubMed ID: 2476522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
